Disc Medicine, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Disc Medicine, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $687.00K, a 139.37% increase year-over-year.
- Disc Medicine, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $291.00K, a 48.47% increase year-over-year.
- Disc Medicine, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $287.00K, a 17.14% increase year-over-year.
- Disc Medicine, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $196.00K.
- Disc Medicine, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $578.00K, a 31.07% increase from fiscal 2024.
- Disc Medicine, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $441.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-03-31 | $687.00K 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $578.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $291.00K 10-Q · filed 2025-11-06 | |
| 2025-03-31 | $287.00K 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $441.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $196.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $245.00K 10-Q · filed 2025-11-06 | |
| 2022-06-30 | $11.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |